Gilead Sciences, Inc.
GILD · Nasdaq
GILD · Nasdaq
Gilead Sciences develops and sells prescription medicines, with its commercial business centered on HIV treatments and additional products in oncology and liver disease. HIV medicines are the largest identified growth driver in the supplied results; oncology drug Trodelvy and liver-disease treatment Livdelzi also contributed to quarterly growth. The company sells through healthcare systems and serves patients whose treatments are prescribed by healthcare professionals. Product sales rose 13% year over year to $8.3 billion in the third quarter of 2026. For FY2025, Gilead reported $29.4 billion in revenue and $8.5 billion in net income, compared with $28.8 billion and $0.5 billion, respectively, in FY2024.
Gilead rose 5.36%, from $157.19 to $165.61, with the decisive move coming after its October 29 third-quarter results. Shares advanced gradually from Monday through Wednesday, then jumped $6.41 on Thursday as the company beat earnings and revenue estimates and reported product sales up 13% year over year to $8.3 billion. HIV medicines, Trodelvy and Livdelzi drove the growth, and Gilead raised its 2026 product-sales outlook. The results and higher sales guidance outweighed the reported cut to EPS outlook and concerns about future pricing pressure, including a projected $1.5 billion Biktarvy headwind in 2028. Trading volume also rose to 8.4 million shares Thursday, above the roughly 4.9–6.0 million shares on the preceding three sessions.
Gilead shares gained 1.75%, rising from $150.43 to $153.07 over the reported period. The path was volatile: the stock fell to $147.92 on Oct. 13, rebounded to $153.54 on Oct. 14 and reached a period high close of $157.37 on Oct. 15, then retreated to $153.07 by Oct. 19. Trading volume was highest on Oct. 15, at 8.3 million shares. The evidence includes a report that Gilead agreed to buy an experimental inflammatory bowel disease pill, a Zacks upgrade, a Bank of America target increase and pre-quarter earnings optimism, but it does not date or link those items to the daily moves. ETF activity was mixed, with reports of both inflows and net selling; no market benchmark context is supplied.
Gilead shares gained 4.01%, rising from $144.63 to $150.43 across the supplied weekly endpoints. The advance was uneven: the stock slipped from $144.63 on Oct. 5 to $144.23 on Oct. 6, then climbed for three sessions to $151.17 on Oct. 9 before giving back $0.74 on Oct. 12. The strongest daily rise came between Oct. 8 and Oct. 9, when the close advanced to $151.17. The supplied evidence does not identify a company-specific announcement or a market-wide catalyst explaining that run, so the move is best described as a rally without an evidenced news driver. Gilead had scheduled Q3 results and guidance for Oct. 29.
Gilead fell 4.66%, from $151.28 on September 29 to $144.23 on October 6, with the decline extending across the supplied closes and no material reversal. The stock dropped to $144.74 by October 2, then slipped again to $144.63 on October 5 and $144.23 on October 6; October 5 had the highest volume in the listed sessions. The supplied evidence identifies no company-specific operating announcement that explains the selling. Analyst coverage was mixed, with Truist and Morgan Stanley target cuts and a JPMorgan target increase, but the evidence does not establish that these changes drove the trading. No broad-market comparison is supplied to explain the move in market context.
Gilead fell $2.19, or 1.46%, from $149.69 to $147.50 over the stated week. It advanced to $152.21 on Monday, September 28, then reversed over the next three sessions, closing lower each day and giving back more than the Monday rise. The supplied evidence does not identify a company-specific catalyst for the decline. A BNK Invest report noted a $614.7 million week-over-week inflow to the broad health-care XLV ETF, but did not attribute that flow to Gilead or explain the share-price move. No market benchmark or other market-wide performance data are supplied to establish a broader trading context.
Gilead rose 2.50% over the reported period, from $147.68 to $151.37. The advance was concentrated at the start: shares climbed to $150.89 on September 17, then eased to $150.11 on September 18, a partial reversal. They recovered to $150.56 on September 21 and gained again to $152.67 on September 22 before slipping to $151.37 on September 23. The supplied evidence does not identify a company-specific announcement behind the move; Zacks noted the 1.40% September 22 session gain but supplied no catalyst. No market benchmark is provided to explain the trading in broader-market terms.
Gilead Sciences rose $0.30, or 0.21%, over the week, from $146.34 to $146.64. The move was not a steady advance: the stock climbed to $149.92 on September 1 and $151.22 on September 3 before giving back nearly all of those gains in the September 8 session, when it fell 2.89% to $146.64 on 6.1 million shares. The supplied evidence does not identify a company-specific announcement, earnings release, or guidance change explaining the reversal. Instead, the stock moved without a documented company catalyst, with trading concentrated around the sharp late-week decline. Articles discussing approvals, analyst views, and investment plans provide broader context but no clearly dated weekly trigger.
Gilead shares rose $2.36, or 1.59%, from $148.86 to $151.22 over the stated week. The stock first recovered from a $146.34 close on Monday, gained 2.45% on Tuesday to $149.92, slipped modestly Wednesday, and then added 1.08% Thursday. The most important company-specific catalyst was optimism surrounding accelerated FDA approval for an HDV treatment, while separate coverage highlighted FDA approval of Bixlenvo as a new single-tablet HIV option. Positive research framing, including a Zacks Strong Buy upgrade and reports describing Gilead as a quality dividend stock, supported sentiment. A reported sale of 15,000 shares by the CEO near $150 was a counterpoint, but did not prevent the late-week advance.
Gilead fell $0.44, or 0.30%, over the week, closing at $145.68 versus $146.12 on August 21. The stock rose $0.62 on Monday and another $2.03 on Tuesday, then eased $0.68 on Wednesday and added $0.77 on Thursday as investors focused on the European Commission’s Trodelvy-Keytruda approval and the expected FDA decision on Bixlenvo. Thursday’s FDA approval of once-daily Bixlenvo for virologically suppressed adults with HIV did not prevent a sharp Friday reversal: shares dropped $3.18, giving back the week’s gains. No negative company-specific announcement was supplied for Friday; a reported health-care ETF outflow that included GILD provided broader sector context.
Gilead rose $3.00, or 2.30%, from $130.21 to $133.21 over the week. The advance was volatile: shares gained $0.94 on Monday and jumped another $4.10 on Tuesday to $135.25, then gave back most of that move over the next two sessions, falling $3.49 on Wednesday and $0.90 on Thursday. Friday brought a $2.35 rebound to finish at the weekly high. Trading volume increased during the reversal, reaching 11.38 million shares on Wednesday. The supplied evidence does not identify a company-specific announcement, guidance change, or analyst action during the week, so the move appears driven by trading around recent strength and broader market factors that are not specified.
Gilead rose $0.93, or 0.69%, from $134.32 to $135.25, reversing a four-session slide that carried the stock to $130.21 by July 31. The main catalyst was anticipation of, and reporting around, second-quarter results on August 4: Gilead posted a 5.92% revenue surprise and a 4.53% earnings surprise despite reporting a quarterly loss, while revenue grew at a double-digit rate. The loss reflected more than $11 billion of acquired in-process research and development charges tied to recent acquisitions. The stock gained $4.10 on August 4, on volume of 10.1 million shares, recovering most of the prior decline; no separate market-wide driver was provided.
